Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity

PLoS Pathogens

Volumn 7, Issue 6, 2011, Pages

  Haim, Hillel ^a   Strack, Bettina ^a   Kassa, Aemro ^a   Madani, Navid ^a   Wang, Liping ^a   Courter, Joel R ^b   Princiotto, Amy ^a   McGee, Kathleen ^a   Pacheco, Beatriz ^a   Seaman, Michael S ^c   Smith III, Amos B ^b   Sodroski, Joseph ^a,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; VIRUS RECEPTOR;

ANTIGEN BINDING; ARTICLE; CD4+ T LYMPHOCYTE; COLD EXPOSURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION; NUCLEOTIDE SEQUENCE; RECEPTOR BINDING; VIRUS ENTRY; VIRUS INHIBITION; BINDING SITE; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PATHOGENICITY; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

BINDING SITES; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VARIATION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; NEUTRALIZATION TESTS; RECEPTORS, VIRUS; VIRUS INTERNALIZATION;

EID: 79959845498     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1002101     Document Type: Article

References (94)

1. Wyatt R, Sodroski J, (1998) The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280: 1884-1888.
2. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S, (2008) Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113.
3. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97: 9026-9031.
4. Allan JS, (1991) Receptor-mediated activation of immunodeficiency viruses in viral fusion. Science 252: 1322-1323.
5. Allan JS, Strauss J, Buck DW, (1990) Enhancement of SIV infection with soluble receptor molecules. Science 247: 1084-1088.
6. Dalgleish AG, Beverley PC, Clapham PR, Crawford DH, Greaves MF, et al. (1984) The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 312: 763-767.
7. Klatzmann D, Champagne E, Chamaret S, Gruest J, Guetard D, et al. (1984) T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 312: 767-768.
8. Ray N, Doms RW, (2006) HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 303: 97-120.
9. Berger EA, Murphy PM, Farber JM, (1999) Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol 17: 657-700.
10. Chan DC, Chutkowski CT, Kim PS, (1998) Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A 95: 15613-15617.
11. Tan K, Liu J, Wang J, Shen S, Lu M, (1997) Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A 94: 12303-12308.
12. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ, (1994) Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A 91: 9770-9774.
13. Kowalski M, Potz J, Basiripour L, Dorfman T, Goh WC, et al. (1987) Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science 237: 1351-1355.
14. Freed EO, Myers DJ, Risser R, (1990) Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41. Proc Natl Acad Sci U S A 87: 4650-4654.
15. Bosch ML, Earl PL, Fargnoli K, Picciafuoco S, Giombini F, et al. (1989) Identification of the fusion peptide of primate immunodeficiency viruses. Science 244: 694-697.
16. Chan DC, Fass D, Berger JM, Kim PS, (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89: 263-273.
17. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC, (1997) Atomic structure of the ectodomain from HIV-1 gp41. Nature 387: 426-430.
18. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, et al. (2002) Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol 76: 6277-6292.
19. Kolchinsky P, Mirzabekov T, Farzan M, Kiprilov E, Cayabyab M, et al. (1999) Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication. J Virol 73: 8120-8126.
20. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, et al. (1999) Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc Natl Acad Sci U S A 96: 6359-6364.
21. Dumonceaux J, Nisole S, Chanel C, Quivet L, Amara A, et al. (1998) Spontaneous mutations in the env gene of the human immunodeficiency virus type 1 NDK isolate are associated with a CD4-independent entry phenotype. J Virol 72: 512-519.
22. Taylor BM, Foulke JS, Flinko R, Heredia A, DeVico A, et al. (2008) An alteration of human immunodeficiency virus gp41 leads to reduced CCR5 dependence and CD4 independence. J Virol 82: 5460-5471.
23. Xiao P, Usami O, Suzuki Y, Ling H, Shimizu N, et al. (2008) Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (C-X-C motif) receptor 4. AIDS 22: 1749-1757.
24. Zerhouni B, Nelson JA, Saha K, (2004) Isolation of CD4-independent primary human immunodeficiency virus type 1 isolates that are syncytium inducing and acutely cytopathic for CD8+ lymphocytes. J Virol 78: 1243-1255.
25. Bhattacharya J, Peters PJ, Clapham PR, (2003) CD4-independent infection of HIV and SIV: implications for envelope conformation and cell tropism in vivo. AIDS 17 (Suppl 4): S35-43.
26. Edinger AL, Mankowski JL, Doranz BJ, Margulies BJ, Lee B, et al. (1997) CD4-independent, CCR5-dependent infection of brain capillary endothelial cells by a neurovirulent simian immunodeficiency virus strain. Proc Natl Acad Sci U S A 94: 14742-14747.
27. Reeves JD, Doms RW, (2002) Human immunodeficiency virus type 2. J Gen Virol 83: 1253-1265.
28. Reeves JD, Hibbitts S, Simmons G, McKnight A, Azevedo-Pereira JM, et al. (1999) Primary human immunodeficiency virus type 2 (HIV-2) isolates infect CD4-negative cells via CCR5 and CXCR4: comparison with HIV-1 and simian immunodeficiency virus and relevance to cell tropism in vivo. J Virol 73: 7795-7804.
29. LaBranche CC, Hoffman TL, Romano J, Haggarty BS, Edwards TG, et al. (1999) Determinants of CD4 independence for a human immunodeficiency virus type 1 variant map outside regions required for coreceptor specificity. J Virol 73: 10310-10319.
30. Edwards TG, Wyss S, Reeves JD, Zolla-Pazner S, Hoxie JA, et al. (2002) Truncation of the cytoplasmic domain induces exposure of conserved regions in the ectodomain of human immunodeficiency virus type 1 envelope protein. J Virol 76: 2683-2691.
31. Kolchinsky P, Kiprilov E, Sodroski J, (2001) Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variants. J Virol 75: 2041-2050.
32. Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, et al. (2002) A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 76: 644-655.
33. Thomas ER, Shotton C, Weiss RA, Clapham PR, McKnight A, (2003) CD4-dependent and CD4-independent HIV-2: consequences for neutralization. AIDS 17: 291-300.
34. Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, et al. (2002) CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76: 2595-2605.
35. Cheng-Mayer C, Brown A, Harouse J, Luciw PA, Mayer AJ, (1999) Selection for neutralization resistance of the simian/human immunodeficiency virus SHIVSF33A variant in vivo by virtue of sequence changes in the extracellular envelope glycoprotein that modify N-linked glycosylation. J Virol 73: 5294-5300.
36. Mo H, Stamatatos L, Ip JE, Barbas CF, Parren PW, et al. (1997) Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off. J Virol 71: 6869-6874.
37. Park EJ, Vujcic LK, Anand R, Theodore TS, Quinnan GV Jr, (1998) Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes. J Virol 72: 7099-7107.
38. Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, et al. (2004) The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321: 8-22.
39. O'Rourke SM, Schweighardt B, Scott WG, Wrin T, Fonseca DP, et al. (2009) Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J Virol 83: 7728-7738.
40. O'Rourke SM, Schweighardt B, Phung P, Fonseca DP, Terry K, et al. (2005) Mutation at a single position in the V2 domain of the HIV-1 envelope protein confers neutralization sensitivity to a highly neutralization-resistant virus. J Virol 84: 11200-11209.
41. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH, (1995) Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera. J Virol 69: 39-48.
42. Cayabyab M, Karlsson GB, Etemad-Moghadam BA, Hofmann W, Steenbeke T, et al. (1999) Changes in human immunodeficiency virus type 1 envelope glycoproteins responsible for the pathogenicity of a multiply passaged simian-human immunodeficiency virus (SHIV-HXBc2). J Virol 73: 976-984.
43. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J, (2001) Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 75: 3435-3443.
44. Johnson WE, Morgan J, Reitter J, Puffer BA, Czajak S, et al. (2002) A replication-competent, neutralization-sensitive variant of simian immunodeficiency virus lacking 100 amino acids of envelope. J Virol 76: 2075-2086.
45. Xiang SH, Farzan M, Si Z, Madani N, Wang L, et al. (2005) Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody. J Virol 79: 6068-6077.
46. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, et al. (2007) Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317: 1930-1934.
47. Haim H, Si Z, Madani N, Wang L, Courter JR, et al. (2009) Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 5: e1000360.
48. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, et al. (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 70: 1100-1108.
49. Thali M, Moore JP, Furman C, Charles M, Ho DD, et al. (1993) Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 67: 3978-3988.
50. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
51. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, et al. (1996) CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 384: 179-183.
52. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, et al. (1996) CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 384: 184-187.
53. Si Z, Madani N, Cox JM, Chruma JJ, Klein JC, et al. (2004) Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci U S A 101: 5036-5041.
54. Furuta RA, Wild CT, Weng Y, Weiss CD, (1998) Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 5: 276-279.
55. He Y, Vassell R, Zaitseva M, Nguyen N, Yang Z, et al. (2003) Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 77: 1666-1671.
56. Rowell JF, Stanhope PE, Siliciano RF, (1995) Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC. J Immunol 155: 473-488.
57. Berlioz-Torrent C, Shacklett BL, Erdtmann L, Delamarre L, Bouchaert I, et al. (1999) Interactions of the cytoplasmic domains of human and simian retroviral transmembrane proteins with components of the clathrin adaptor complexes modulate intracellular and cell surface expression of envelope glycoproteins. J Virol 73: 1350-1361.
58. Kassa A, Madani N, Schon A, Haim H, Finzi A, et al. (2009) Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol 83: 8364-8378.
59. Xiang SH, Kwong PD, Gupta R, Rizzuto CD, Casper DJ, et al. (2002) Mutagenic stabilization and/or disruption of a CD4-bound state reveals distinct conformations of the human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 76: 9888-9899.
60. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
61. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326: 1123-1127.
62. Kang SM, Quan FS, Huang C, Guo L, Ye L, et al. (2005) Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 331: 20-32.
63. Kassa A, Finzi A, Pancera M, Courter JR, Smith AB 3rd, et al. (2009) Identification of a human immunodeficiency virus type 1 envelope glycoprotein variant resistant to cold inactivation. J Virol 83: 4476-4488.
64. Finzi A, Xiang SH, Pacheco B, Wang L, Haight J, et al. (2010) Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 37: 656-667.
65. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, et al. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173: 340-348.
66. Moore JP, Cao Y, Qing L, Sattentau QJ, Pyati J, et al. (1995) Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120. J Virol 69: 101-109.
67. Si Z, Cayabyab M, Sodroski J, (2001) Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys. J Virol 75: 4208-4218.
68. Harouse JM, Gettie A, Tan RC, Blanchard J, Cheng-Mayer C, (1999) Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284: 816-819.
69. Klasse PJ, McKeating JA, Schutten M, Reitz MS Jr, Robert-Guroff M, (1993) An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. Virology 196: 332-337.
70. Park EJ, Gorny MK, Zolla-Pazner S, Quinnan GV Jr, (2000) A global neutralization resistance phenotype of human immunodeficiency virus type 1 is determined by distinct mechanisms mediating enhanced infectivity and conformational change of the envelope complex. J Virol 74: 4183-4191.
71. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, et al. (2005) Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 79: 10103-10107.
72. Seaman MS, Leblanc DF, Grandpre LE, Bartman MT, Montefiori DC, et al. (2007) Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens. Virology 367: 175-186.
73. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, et al. (2010) Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol 84: 1439-1452.
74. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, et al. (2005) Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 201: 1407-1419.
75. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, et al. (2003) Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 77: 10557-10565.
76. Privalov PL, (1990) Cold denaturation of proteins. Crit Rev Biochem Mol Biol 25: 281-305.
77. Schenten D, Marcon L, Karlsson GB, Parolin C, Kodama T, et al. (1999) Effects of soluble CD4 on simian immunodeficiency virus infection of CD4-positive and CD4-negative cells. J Virol 73: 5373-5380.
78. White TA, Bartesaghi A, Borgnia MJ, Meyerson JR, de la Cruz MJ, et al. (2010) Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure. PLoS Pathog 6: e1001249.
79. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, et al. (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
80. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
81. Raja A, Venturi M, Kwong P, Sodroski J, (2003) CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5. J Virol 77: 713-718.
82. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, et al. (1991) An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 146: 4325-4332.
83. Moore PL, Crooks ET, Porter L, Zhu P, Cayanan CS, et al. (2006) Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J Virol 80: 2515-2528.
84. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
85. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, et al. (1994) Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 68: 4821-4828.
86. Earl PL, Broder CC, Doms RW, Moss B, (1997) Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein. J Virol 71: 2674-2684.
87. Korber B, Foley B, Kuiken C, Pillai S, Sodroski J, (1998) Human Retroviruses and AIDS. Los Alamos Los Alamos Natl Lab.
88. Yang X, Tomov V, Kurteva S, Wang L, Ren X, et al. (2004) Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1. J Virol 78: 12975-12986.
89. Madani N, Schön A, Princiotto AM, Lalonde JM, Courter JR, et al. (2008) Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 16: 1689-1701.
90. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J, (1995) Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 69: 4413-4422.
91. Heckman KL, Pease LR, (2007) Gene splicing and mutagenesis by PCR-driven overlap extension. Nat Protoc 2: 924-932.
92. Kwong PD, Wyatt R, Desjardins E, Robinson J, Culp JS, et al. (1999) Probability analysis of variational crystallization and its application to gp120, the exterior envelope glycoprotein of type 1 human immunodeficiency virus (HIV-1). J Biol Chem 274: 4115-4123.
93. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, et al. (2005) Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 79: 10108-10125.
94. Rho HM, Poiesz B, Ruscetti FW, Gallo RC, (1981) Characterization of the reverse transcriptase from a new retrovirus (HTLV) produced by a human cutaneous T-cell lymphoma cell line. Virology 112: 355-360.